Daiichi Sankyo

11:45 AM - 12:00 PM, Tuesday, June 4, 2019 ・ Theater 1
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with a Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit www.daiichisankyo.com
Ticker:
4568
Exchange:
TSE
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Japan
Year Founded:
Not Provided.
Main Therapeutic Focus:
Lead Product in Development:
DS-8201
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Global Head of Business Development
Daiichi Sankyo